The impact of vancomycin susceptibility on treatment outcomes among patients with methicillin resistant Staphylococcus aureusbacteremia

Health Care–Associated Invasive MRSA Infections, 2005-2008

(2010) Alexander J. Kallen   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Paradoxical Relationship between the Clinical Outcome ofStaphylococcus aureusBacteremia and the Minimum Inhibitory Concentration of Vancomycin

(2009) James Price et al.   CLINICAL INFECTIOUS DISEASES

Relationship between Initial Vancomycin Concentration‐Time Profile and Nephrotoxicity among Hospitalized Patients

(2009) Thomas P. Lodise et al.   CLINICAL INFECTIOUS DISEASES

Vancomycin MIC plus Heteroresistance and Outcome of Methicillin-Resistant Staphylococcus aureus Bacteremia: Trends over 11 Years

(2009) A. C. Musta et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists

(2008) M. Rybak et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Relationship between Vancomycin MIC and Failure among Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia Treated with Vancomycin

(2008) T. P. Lodise et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Impact of Routine Infectious Diseases Service Consultation on the Evaluation, Management, and Outcomes ofStaphylococcus aureusBacteremia

(2008) Timothy C. Jenkins et al.   CLINICAL INFECTIOUS DISEASES

Influence of Vancomycin Minimum Inhibitory Concentration on the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia

(2007) A. Soriano et al.   CLINICAL INFECTIOUS DISEASES